ANNUAL RESULTS 2021
DISCUSSION
Andreas Eckert
CEO & Founder
30 March 2022
A Diversified Global Specialist for Radioactive Applications
ISOTOPE
PRODUCTS
Industry
Radiation
Sources
Services
Trade
Disposal
MEDICAL
Medicine
Medical Devices
Pharmaceuticals
Lab Devices
Engineering
HOLDING
Group Items/
Pipeline
Pentixa
Myelo
Special projects
Engine
+++
180.4 million EUR Revenues in FY 2021 | |
2 | 34.5 million EUR Net Income |
- 900 Employees (Headcounts)
19 Sites Worldwide
Results 2021
(EUR million)
Since January 3rd, 2022
Tecnonuclear
3 Buenos Aires
Revenues | 180.4 |
Net Income | 34.5 |
NI/ Sales = 19%
3%
11%
39%
47%
America | Europe | Asia | Middle East & Africa |
Slides only for illustration - the spoken word shall be binding
In the Middle of a Rapidly Growing Attractive Market
4
Annual Results Discussion
2021 IN REVIEW
5
Um den Rest dieser Noodl zu lesen, rufen Sie bitte die Originalversion auf, und zwar hier.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Eckert & Ziegler AG published this content on 11 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2022 17:11:06 UTC.